IDEXX Laboratories, Inc. $IDXX Stock Holdings Lowered by Premier Fund Managers Ltd

Premier Fund Managers Ltd lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,102 shares of the company’s stock after selling 63,026 shares during the quarter. IDEXX Laboratories comprises about 2.2% of Premier Fund Managers Ltd’s holdings, making the stock its 10th largest holding. Premier Fund Managers Ltd owned approximately 0.10% of IDEXX Laboratories worth $52,428,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Semanteon Capital Management LP purchased a new position in shares of IDEXX Laboratories in the third quarter valued at $567,000. Lansforsakringar Fondforvaltning AB publ lifted its holdings in IDEXX Laboratories by 3.8% in the 3rd quarter. Lansforsakringar Fondforvaltning AB publ now owns 26,459 shares of the company’s stock worth $16,904,000 after buying an additional 963 shares in the last quarter. Advyzon Investment Management LLC acquired a new position in IDEXX Laboratories in the 3rd quarter worth $236,000. Citigroup Inc. boosted its position in IDEXX Laboratories by 5.6% in the 3rd quarter. Citigroup Inc. now owns 144,452 shares of the company’s stock valued at $92,289,000 after buying an additional 7,670 shares during the last quarter. Finally, Stevens Capital Management LP grew its stake in shares of IDEXX Laboratories by 31.7% during the third quarter. Stevens Capital Management LP now owns 1,611 shares of the company’s stock valued at $1,029,000 after acquiring an additional 388 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director owned 648 shares of the company’s stock, valued at $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 18,180 shares of company stock worth $11,626,996 over the last quarter. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $635.66 on Friday. The stock has a market capitalization of $50.76 billion, a PE ratio of 48.64, a price-to-earnings-growth ratio of 3.87 and a beta of 1.67. The business’s fifty day moving average price is $677.74 and its 200 day moving average price is $669.01. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the firm earned $2.53 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

Analysts Set New Price Targets

Several research firms recently commented on IDXX. BTIG Research cut their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. UBS Group decreased their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Morgan Stanley raised their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.